ClinicalTrials.gg
RecruitingNCT06102590OXYTRIPUpdated Jul 31, 2026

Oxygen Extraction-guided Transfusion

An interventional study of Individualized red blood cell transfusion strategy and European guidelines red blood cell transfusion strategy in Blood Transfusion, sponsored by Università degli Studi di Ferrara. Recruiting at 4 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-31.

Sponsored by Università degli Studi di Ferrara · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Nov 2023; still recruiting 3 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
324
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

In critically ill patients, optimized strategies for red blood cells transfusion (RBCT) are still controversial. Most recent guidelines suggest that clinical practice in ICU setting should follow a restrictive approach to RBCT (i.e., hemoglonim level \< 7.0 g/dL).In our previous study, oxygen extraction ratio (O2ER) has shown good performance as a marker to identify the correct timing for RBCT, potentially affecting 90-day mortality in non-bleeding, critically ill patients [11]. Moreover, our data suggested that an individualized strategy for RBCT may reduce the incidence of acute kidney injury (AKI), which is possibly related to a better delivery of oxygen and organ perfusion.

02

Conditions studied

  • Blood Transfusion
03

In context

Lead sponsor

Università degli Studi di Ferrara is the lead sponsor of 65 studies on the registry; 10 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • levels ≤ 9.0 g/dL (as confirmed through a blood test and/or through blood gas analysis)
  • Presence of an arterial line and a central venous line (either jugular or subclavian), with confirmed correct position of the catheter tip at the atrio-caval junction (allowing correct estimation of central venous saturation, ScvO2).

Exclusion criteria

Exclusion Criteria:

  • Age \< 18 years;
  • Pregnancy
  • Clinical evidence of acute bleeding
  • Diagnosis of haematological
  • Diagnosis of sickle cell disease, or other diseases exposing the patient to chronic RCBTs
  • Acquired or congenital disorders of coagulation
  • Patients with ongoing AKI of stage 1 or worse and/or known chronic kidney disease (CKD) of stage G3a or worse, defined as below 60 for a minimum of 3 months
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
324 participants (estimated)

Study arms

  • Experimental
    Individualized RBCT

    Requires daily assessment of hemoglobin (Hb) levels. Prescription of RCBT is restricted to patients who present Hb ≤ 9.0 g/dL and O2ER ≥ 30%. If O2ER \< 30%, transfusion will take place only when Hb falls below 7.0 g/dL. Further O2ER measurements during the day in this group are allowed, and the clinician should not be blinded of the results. To tolerate Hb levels below 7.0 g/dL with O2ER \< 30% remains a clinical decision, documented in the CRF. Transfusion with Hb below 6.0 g/dL is mandatory

    Other: Individualized red blood cell transfusion strategy

  • Active comparator
    Control group

    Requires daily assessment of hemoglobin levels. Prescription of RCBT is restricted to patients who present Hb ≤ 7.0 g/dL, despite of O2ER values. Indeed, O2ER calculation takes place at least once daily in this group but does not interfere with clinical decision to prescribe RBCT. A liberal transfusion threshold (i.e. 9.0 g/dL) is still possible in critically ill adults with acute coronary syndromes, as indicated by the European current guidelines

    Other: European guidelines red blood cell transfusion strategy

Interventions

  • OtherIndividualized red blood cell transfusion strategy

    Prescription of RCBT is restricted to patients who present Hb ≤ 9.0 g/dL and O2ER ≥ 30%.

  • OtherEuropean guidelines red blood cell transfusion strategy

    RBCT according to ESICM guidelines

06

What researchers measure

Primary outcomes

  1. Acute Kidney Injury (AKI)

    Primary outcome will be the incidence of AKI, according to KDIGO latest definitions

    Time frame: 7-day after study inclusion

Secondary outcomes

  1. 90-day mortality

    Time frame: 90-day after study inclusion

  2. proportion of patients undergoing RBCT, despite adequate/low O2ER

    Patients receiving RBCT with O2ER\<30%

    Time frame: 28 days

  3. SOFA score variations

    SOFA score at study inclusion-SOFA score at day 5

    Time frame: 5 days

  4. variations in myocardial-specific troponin

    variations in myocardial-specific troponin

    Time frame: 24 hours after study inclusion

  5. days on vasopressors

    number of days on vasopressor therapy

    Time frame: 28 days

  6. Major Adverse Kidney Events by 90 days (MAKE90)

    composite of death, new renal replacement therapy, or persistent renal dysfunction

    Time frame: 90 days

  7. ICU mortality

    ICU mortality

    Time frame: through study completion, an average of 180 days

  8. In-hospital mortality

    In-hospital mortality

    Time frame: through study completion, an average of 180 days

07

Study locations

4 of 4 sites recruiting
08

References and documents

Publications

  • Fogagnolo A, Azzolina D, Taccone FS, Pedarzani E, Pasa G, Marianello D, Valpiani G, Marchesini C, Annoni F, Moureau A, Volta CA, Franchi F, Spadaro S. Oxygen extraction-guided transfusion strategy in critically ill patients: study protocol for a randomised, open-labelled, controlled trial. BMJ Open. 2024 Nov 12;14(11):e089910. doi: 10.1136/bmjopen-2024-089910. PubMed 39532348 ↗

Individual participant data

Plan to share: Yes — To be shared under reasonable requests.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2023 (actual). Primary completion is estimated for Dec 2026, 36 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 18, 2023
First posted
Oct 26, 2023
StartActual
Nov 4, 2023
Primary completionEst.
Dec 1, 2026
CompletionEst.
Mar 1, 2027
Last update
Jul 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06102590
Lead sponsor
Università degli Studi di Ferrara
Responsible party
Alberto Fogagnolo (Dr, Università degli Studi di Ferrara) — Principal investigator
First posted
Oct 26, 2023
Start date
Nov 4, 2023
Primary completion
Dec 1, 2026 (estimated)
Completion
Mar 1, 2027 (estimated)
Last update
Jul 31, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion